However, nivolumab did not reach statistical significance for overall survival compared to sorafenib, despite exhibiting the clinical benefits of improved objective response rate, long-time disease control, fewer adverse events, and survival benefit. 16 Only a subset of patients with advanced HCC experience clinical benefits through TKIs or ICIs therapy.
← all excerpts
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report.
1
—
—